BioPharmX to show topical minocycline fights P. acnes-induced inflammation
BioPharmX will share research findings this week that suggest topical minocycline fights P. acnes-induced inflammation in human keratinocytes. The data will be shared in a poster presentation titled "Effects of minocycline against Propionibacterium acnes-induced inflammation in human keratinocytes," at the ASCB Annual Meeting in San Francisco Tuesday. The study, part of BioPharmX's assessment of the effectiveness of its unique BPX-01 topical minocycline formulation, suggests that the effectiveness of minocycline's anti-inflammatory properties against P. acnes-stimulated keratinocytes may be realized in a topical formulation. Recent studies found that inflammation - long thought to be a side-effect of P. acnes - may actually be the underlying cause of acne. That would mean any formulation that delivers minocycline's anti-inflammatory benefits of lesion count and lesion size reduction - as well as its antibacterial benefits - would optimize the drug's therapeutic value for prescribing physicians.